Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 August 2021 | Story Ruan Bruwer
Louzanne Coetzee at the Paralympics in Tokyo with her two guides, Claus Kempen (left) and Estean Badenhorst. She is one of 34 members in Team South Africa.

For some athletes, the postponement of the Paralympics was a big frustration, but for Louzanne Coetzee it was a ‘blessing in disguise’.

According to the former University of the Free State (UFS) student and current Residence Head of Akasia on the UFS Bloemfontein Campus, she was more than happy to get another 12 months to prepare herself to the very best of her ability. She will be in action at the Tokyo Paralympics in the 1 500 m on Sunday (29 August 2021) and Monday (30 August). On 5 September, she will tackle the marathon. It is her second Paralympics. 

“This is the most exited I have ever been for an event. It has been so long since I was able to compete on a high level. I think it is a blessing in disguise. It allowed me more time to prepare. I’m in a great state and I cannot wait,” she said.

In the 1 500 m, Coetzee will be guided by Estean Badenhorst. In the marathon she will run next to Claus Kempen, with whom she has completed a couple of marathons before.
“They are both very experienced and I’m fortunate to have such a great team with me. When you are running an event like the 1 500 m, you need to fully trust your guide with his decision making.”

“The main focus is the track item. I won’t put too much pressure on myself in the marathon. The prime goal is to gain experience in the longer distance, because that is where I’ll be shifting in the future,” she explained.

The South African 1 500 m record holder in the T11 classification (totally blind) clocked a personal best time of 4:51.65 in 2019. She is the world record holder in the 5 000 m; however, the item does not feature on the Paralympic programme. 

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept